key: cord-0684455-zoo08jyw
authors: Gimenez, E.; Alberola, J.; Torres, I.; Albert, E.; Alcaraz, M. J.; Botija, P.; Amat, P.; Remigia, M. J.; Beltran, M. J.; Rodado, C.; Huntley, D.; Olea, B.; Navarro, D.
title: Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty COVID-19 vaccine
date: 2021-10-07
journal: nan
DOI: 10.1101/2021.10.06.21264616
sha: daa5a7409c0fa73c6d023c5474f276a95844fccf
doc_id: 684455
cord_uid: zoo08jyw

Objectives: There is scarce information as to the durability of immune responses elicited by the Comirnaty COVID-19 vaccine in nursing home residents. Here, we assessed SARS-CoV-2-Spike (S)-targeted antibody and functional T cell responses at around 6 months after complete vaccination. Methods: The sample comprised 46 residents (34 females; age, 60-100 years), of whom 10 had COVID-19 prior to vaccination. Baseline (median of 17.5 days after vaccination) and follow-up (median, 195 days) plasma specimens were available for quantitation of SARS-CoV-2-S antibodies and enumeration of SARS-CoV-2-S-reactive IFN-{gamma} CD4+ and CD8+ T cells by flow cytometry. Results: In total, 44/45 participants had detectable SARS-CoV-2-S antibodies at follow-up. Overall, antibody levels were found to decrease (median, 4.8 fold). Antibodies waning was more frequent (P<0.001) in SARS-CoV-2 naive (29/35) than in recovered (1/10) residents. SARS-CoV-2-S IFN-{gamma} CD8+ T cells were detected in 33/46 and 24/46 at baseline and follow-up, respectively. The figures for CD4+ T cell counterparts were 12/46 and 30/46. Detectable SARS-CoV-2 IFN-{gamma} CD8+ and CD4+ T cell responses at follow-up were more common in recovered (8/10 and 7/10, respectively) than in naive residents (9/36 and 25/36, respectively). For those with detectable responses at both time points, SARS-CoV-2-S IFN-{gamma} CD8+ T cell frequencies decreased significantly (P=0.001) over time whereas the opposite (P=0.01) was observed in CD4+ T cells. Conclusion: Almost all residents displayed detectable SARS-CoV-2-S-reactive antibodies and T cell responses, respectively, by around 6 months after complete vaccination with Comirnaty COVID-19 vaccine, albeit generally waning in magnitude over time. Keywords: SARS-CoV-2, Comirnaty COVID-19 vaccine, SARS-CoV-2-S antibodies; SARS-CoV-2-S T cells, Nursing home residents.

Real-world experience has shown mRNA COVID-19 vaccines to be effective in 56 reducing incidence of both asymptomatic and symptomatic SARS-CoV-2 infections and 57 related deaths in nursing home residents [1] , congruent with their ability to elicit robust 58 virus-specific T and B cell immune responses in this population group [2] [3] [4] . 59

Nevertheless, maintaining seemingly protective immune responses in these individuals 60 over time may be compromised by the concurrence of older age, frailty and co-61 morbidities. To shed light on this issue, here we assessed SARS-CoV-2-Spike (S)-62 targeted antibody and functional T cell responses at around 6 months after vaccination 63 with Comirnaty® (Pfizer-BioNTech) in a previously recruited cohort [2] . 64

Out of 53 nursing home residents enrolled in a previous study [2] with data on B and T 67 cell immunity at a median of 17.5 days (range, 14−35 days) after second vaccine dose 68 (baseline sample), 46 (44 females; median age, 89 years; range, 60−100; Supplementary 69 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Company Biosciences, San Jose, CA) as previously described [2] . 85

Differences between medians were compared using the Mann-Whitney U-test or 87

Wilcoxon test for unpaired and paired data, when appropriate. The Spearman rank test 88 was used for correlation analyses between continuous variables. Two-sided exact P-89 values were reported. A P-value <0.05 was considered statistically significant. The 90 analyses were performed using SPSS version 20.0 (SPSS, Chicago, IL, USA). 91

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Of the 46 residents, 10 (21.7%) had evidence of SARS-CoV-2 infection at baseline, as 94 determined by both RT-PCR on nasopharyngeal specimens and detection of N-specific 95 antibodies. No additional residents developed N-specific antibodies between sampling 96 times. 97

Data on SARS-CoV-2-RBD antibody levels were available for 45 participants. All 43 99 residents who tested positive at baseline also displayed detectable responses at follow-100 up, although overall, antibody levels were found to decrease significantly, by a median 101 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 7, 2021. ; https://doi.org/10.1101/2021.10.06.21264616 doi: medRxiv preprint 6 baseline and follow-up, respectively. Nineteen participants developed CD4 + T cell 117 responses between testing time points (median, 0.1%; range, 0.03-1.14%), whereas one 118 out of 12 with detectable responses at baseline had lost this at follow-up ( Figure 2B) . 119

The likelihood of having detectable SARS-CoV-2 IFN-γ CD8 + and CD4 + T at follow-up 120 was higher (P=0.03 and P=0.5) in SARS-CoV-2 recovered (8/10 and 7/10, respectively) 121 than in naïve residents (9/36 and 25/36, respectively). (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 7, 2021. ; https://doi.org/10.1101/2021.10.06.21264616 doi: medRxiv preprint 7 had detectable SARS-CoV-2-S IFN-γ T cells (either CD8 + , CD4 + or both) at follow-up, 141 SARS-CoV-2-S IFN-γ CD4 + T cell responses being more frequently documented than 142 their CD8 + T cells counterparts. Interestingly, recovered COVID-19 residents were 143 more likely to display both CD8 + and CD4 + detectable responses at follow-up than 144 naïve ones. Finally, for those with detectable responses at both sampling times, SARS-145

CoV-2-S IFN-γ CD8 + T cell frequencies decreased significantly, whereas the opposite 146 was observed for CD4 + T cells. In this regard, collectively, the above data suggested 147 that SARS-CoV-2-S IFN-γ CD4 + T cells may develop later than CD8 + T cells in nursing 148 home residents. 149

Limitations of the current study are the relatively small sample size and lack of a control 150 group; regarding the latter, most of the 17 controls included in our previous study [2] 151 were unfortunately not available for follow-up sampling. Secondly, neutralization 152 assays were not carried out. In summary, our data revealed that a large percentage of 153 nursing home residents displayed detectable SARS-CoV-2-S-reactive antibodies and T 154 cell responses, respectively, by around 6 months after complete vaccination with 155

Comirnaty® COVID-19 vaccine, although these generally declined over time. Whether 156 these mid-term immune responses suffice to prevent COVID-19 remains to be 157 determined. Our data also suggested that a booster (third) dose, which has been 158 proposed for elderly people [9,10] may be delayed beyond 6 months in fully vaccinated 159 COVID-19 recovered residents. 160

We are grateful to all personnel who work at nursing home residences affiliated to the 162 Clínico-Malvarrosa Health Department and at Clinic University Hospital, in particular 163 to those at the Microbiology laboratory, for their commitment in the fight against 164

CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home 181 Residents

B and T cell 183 immune responses elicited by the Comirnaty COVID-19 vaccine in nursing-home 184 residents

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Immunogenicity of the BNT162b2 vaccine 187 in frail or disabled nursing home residents: COVID-A study

Antibody response 190 after one and two jabs of the BNT162b2 vaccine in nursing home residents: The 191

CONsort-19 study

Quantitative measurement of anti-SARS-CoV-2 193 antibodies: Analytical and clinical evaluation

Dynamics of 195 antibody response to BNT162b2 vaccine after six months: a longitudinal prospective 196 study

Six-month interim analysis of ongoing immunogenicity surveillance 199 of the mRNA-1273 vaccine in healthcare workers: A third dose is expected

One year later: SARS-CoV-2 immune response and vaccination of healthcare 203 workers post-infection

Efficacy and safety of COVID-19 vaccines in 205 older people

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted October 7, 2021. Briefly, heparinized whole blood (0.5 ml) was simultaneously stimulated for 6 h with 230 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted October 7, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted October 7, 2021. ; https://doi.org/10.1101/2021.10.06.21264616 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the The copyr this version posted October 7, 2021. ; https://doi.org/10.1101/2021.10.06.21264616 doi: medRxiv preprint All rights reserved. No reuse allowed (which was not certified by peer review) is the author/funder, who has gran this versio ; https://doi.org/10.1101/2021.10.06.21264616 doi: medRxiv preprint